Heather N. Reich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heather N. Reich has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Daniel C. Cattran
Toronto Glomerulonephritis Registry, University Health Network, Toronto, Ontario, Canada
2 shared publications- Joan Wither
Schroeder Arthritis Institute, University Health Network, Canada
2 shared publications Michelle A. Hladunewich
Toronto Glomerulonephritis Registry, University Health Network, Toronto, Ontario, Canada
2 shared publicationsAdeera Levin
Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
1 shared publicationAllen Greenwald
Queen's University, Kingston, Ontario, Canada
1 shared publicationAndrew M. Herzenberg
Department of Laboratory Medicine and Pathology, University Health Network and University of Toronto, Toronto, ON, Canada
1 shared publication
Latest Publications
- Open Access
- 4 October 2016
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-12
A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis
Management of lupus nephritis (LN) would be greatly aided by the discovery of biomarkers that accurately reflect changes in disease activity. Here, we used a proteomics approach to identify potential urinary biomarkers associated with LN. Urine was obtained from 60 LN patients with paired renal biopsies, 25 active non-LN SLE patients, and 24 healthy controls. Using Luminex, 128 analytes were quantified and normalized to urinary creatinine levels. Data were analyzed by linear modeling and non-parametric statistics, with corrections for multiple comparisons. A second cohort of 33 active LN, 16 active non-LN, and 30 remission LN SLE patients was used to validate the results. Forty-four analytes were identified that were significantly increased in active LN as compared to active non-LN. This included a number of unique proteins (e.g., TIMP-1, PAI-1, PF4, vWF, and IL-15) as well as known candidate LN biomarkers (e.g., adiponectin, sVCAM-1, and IL-6), that differed markedly (>4-fold) between active LN and non-LN, all of which were confirmed in the validation cohort and normalized in remission LN patients. These proteins demonstrated an enhanced ability to discriminate between active LN and non-LN patients over several previously reported biomarkers. Ten proteins were found to significantly correlate with the activity score on renal biopsy, eight of which strongly discriminated between active proliferative and non-proliferative/chronic renal lesions. A number of promising urinary biomarkers that correlate with the presence of active renal disease and/or renal biopsy changes were identified and appear to outperform many of the existing proposed biomarkers.
- 4 October 2016
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-12
Open AccessA discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis
Management of lupus nephritis (LN) would be greatly aided by the discovery of biomarkers that accurately reflect changes in disease activity. Here, we used a proteomics approach to identify potential urinary biomarkers associated with LN. Urine was obtained from 60 LN patients with paired renal biopsies, 25 active non-LN SLE patients, and 24 healthy controls. Using Luminex, 128 analytes were quantified and normalized to urinary creatinine levels. Data were analyzed by linear modeling and non-parametric statistics, with corrections for multiple comparisons. A second cohort of 33 active LN, 16 active non-LN, and 30 remission LN SLE patients was used to validate the results. Forty-four analytes were identified that were significantly increased in active LN as compared to active non-LN. This included a number of unique proteins (e.g., TIMP-1, PAI-1, PF4, vWF, and IL-15) as well as known candidate LN biomarkers (e.g., adiponectin, sVCAM-1, and IL-6), that differed markedly (>4-fold) between active LN and non-LN, all of which were confirmed in the validation cohort and normalized in remission LN patients. These proteins demonstrated an enhanced ability to discriminate between active LN and non-LN patients over several previously reported biomarkers. Ten proteins were found to significantly correlate with the activity score on renal biopsy, eight of which strongly discriminated between active proliferative and non-proliferative/chronic renal lesions. A number of promising urinary biomarkers that correlate with the presence of active renal disease and/or renal biopsy changes were identified and appear to outperform many of the existing proposed biomarkers.
- 1 January 2012
- Published by Elsevier in Kidney International
- Vol. 81 (2) , 190-195
Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis
- 1 January 2012
- Published by Elsevier in Kidney International
- Vol. 81 (2) , 190-195
Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis
- 1 April 2011
- Published by Elsevier in Kidney International
- Vol. 79 (8) , 914-920
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus
- 1 April 2011
- Published by Elsevier in Kidney International
- Vol. 79 (8) , 914-920
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus